Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

[1]  B. Sharrack,et al.  Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial , 2019, JAMA.

[2]  R. Zivadinov,et al.  Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  K. Sullivan,et al.  Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  A. Rae-Grant.  Author response: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology , 2018, Neurology.

[5]  R. Marrie,et al.  Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis , 2018, Neurology.

[6]  R. Marrie,et al.  Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis , 2018, Neurology.

[7]  F Zipp,et al.  ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis , 2018, European journal of neurology.

[8]  David H. Miller,et al.  ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis , 2018, Multiple sclerosis.

[9]  M. Labopin,et al.  Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. , 2017, Blood advances.

[10]  Jeffrey A. Cohen,et al.  Cell-based therapeutic strategies for multiple sclerosis , 2017, Brain : a journal of neurology.

[11]  M. Sormani,et al.  Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis , 2017, Nature Reviews Neurology.

[12]  M. Sormani,et al.  Autologous hematopoietic stem cell transplantation in multiple sclerosis , 2017, Neurology.

[13]  C. Solano,et al.  Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis , 2017, Neurological Sciences.

[14]  H. Atkins,et al.  Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis , 2017, JAMA neurology.

[15]  D. Arnold,et al.  High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS , 2017, Neurology.

[16]  M. Sormani,et al.  NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs , 2017, Multiple sclerosis.

[17]  Jenny Berg,et al.  New insights into the burden and costs of multiple sclerosis in Europe , 2017, Multiple sclerosis.

[18]  G. Ruiz-Argüelles,et al.  A Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells , 2016, Acta Haematologica.

[19]  D. Arnold,et al.  Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial , 2016, The Lancet.

[20]  S. Crawford,et al.  Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  B. Weinshenker,et al.  Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis , 2015, Neurology.

[22]  K. Schmierer,et al.  Is it time to target no evident disease activity (NEDA) in multiple sclerosis? , 2015, Multiple sclerosis and related disorders.

[23]  S. Crawford,et al.  Guidelines for defining and implementing standard episode of care for hematopoietic stem cell transplantation within the context of clinical trials. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  M. Filippi,et al.  Autologous hematopoietic stem cell transplantation in multiple sclerosis , 2015, Neurology.

[25]  D. Fedorenko,et al.  Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives , 2015, Annals of Hematology.

[26]  H. Weiner,et al.  Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. , 2015, JAMA neurology.

[27]  D. Arnold,et al.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. , 2015, JAMA neurology.

[28]  Daniel C. Lee,et al.  Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. , 2015, JAMA.

[29]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[30]  J. Johansson,et al.  Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[31]  D. Fedorenko,et al.  Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. , 2012, Experimental hematology.

[32]  M. Sormani,et al.  Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience , 2012, Multiple sclerosis.

[33]  H. Atkins,et al.  A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper , 2012, Multiple sclerosis.

[34]  H. Weiner,et al.  Demographic and clinical characteristics of malignant multiple sclerosis , 2011, Neurology.

[35]  E. Havrdová,et al.  High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience , 2010, Multiple sclerosis.

[36]  Yinshan Zhao,et al.  Impact of multiple sclerosis relapses on progression diminishes with time , 2009, Neurology.

[37]  A. Testori,et al.  Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study , 2009, The Lancet Neurology.

[38]  C. Polman,et al.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study , 2009, The Lancet Neurology.

[39]  D. Fedorenko,et al.  High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. , 2008, Experimental hematology.

[40]  S. Vukusic,et al.  Natural history of multiple sclerosis: a unifying concept. , 2006, Brain : a journal of neurology.

[41]  P. Adeleine,et al.  Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. , 2003, Brain : a journal of neurology.